Europe Colistin Market Analysis and Forecast by Size, Share, Growth, Trends 2034

The Europe Colistin Market size is expected to reach US$ 213.2 Million by 2034 from US$ 143.3 Million in 2025. The market is estimated to record a CAGR of 4.6% from 2026 to 2034.

Executive Summary and Europe Colistin Market Analysis:

The colistin market in Europe is growing primarily due to the rising prevalence of multidrug-resistant (MDR) Gram-negative bacterial infections in hospitals and healthcare facilities, where colistin remains a critical last-resort antibiotic for treating severe cases such as bloodstream infections (BSI), sepsis, and lower respiratory tract infections (LRTI). According to the European Centre for Disease Prevention and Control (ECDC), the Antimicrobial Resistance Surveillance in Europe 2024 report (covering 2023 data) showed that carbapenem-resistant Enterobacterales rates increased by an average of 7-9% across many European countries compared to 2022, with MDR Acinetobacter baumannii and Pseudomonas aeruginosa remaining high in Southern and Eastern Europe, thereby driving demand for colistin injectables (IV/IM) in hospital pharmacies. In 2024, ECDC data indicated a further 5-8% rise in MDR infections in several member states, particularly in intensive care units for ventilator-associated pneumonia (VAP).

Europe Colistin Market: Strategic Insights

Europe Colistin Market Segmentation Analysis:

• By Formulation, the Europe Colistin Market is segmented into Injectables (IV or IM), Oral, Topical Formulations, and Inhalation Solutions. The Injectables (IV or IM) segment dominated the market in 2025.
• By Indication, the Europe Colistin Market is segmented into Human Health and Animal Health. The Human Health segment dominated the market in 2025.
• By Human Health, the Europe Colistin Market is segmented into Bloodstream Infections (BSI) and Sepsis Lower, Respiratory Tract Infections (LRTI), Urinary Tract Infections (UTIs), Central Nervous System Infections, Skin Infections, Cystic Fibrosis, Tracheobronchitis or VAP, Gastrointestinal Infections, and Bowel Decontamination. The Respiratory Tract Infections (LRTI) segment dominated the market in 2025.
• By Distribution Channel, the Europe Colistin Market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Channel, and Other Distribution Channel. The Hospital Pharmacy segment dominated the market in 2025.

Europe Colistin Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Colistin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Europe Colistin Market Outlook

In livestock applications, colistin is used for controlling Gram-negative bacterial infections in poultry, swine, and other livestock-intensive farming practices. In poultry production, it targets pathogens such as E. coli and Salmonella spp., helping maintain flock health and productivity in high-density operations. As per the European Medicines Agency, in 2022, nearly 136.5 tonnes of colistin were sold, out of which 99.3% was used for poultry and pig farming. The expansion of poultry farming, driven by surging protein demand, sustains this need, though resistance genes such as mcr-1 have emerged in broiler E. coli. According to the National Institutes of Health, nearly 51.9% of practitioners ceased or avoided colistin use post-restrictions in Europe, while others decreased it by 33.4%. Gastrointestinal diseases in pigs and septicaemia in poultry are key indications driving market growth.

Europe Colistin Market Country Insights

By country, the Europe Colistin Market is segmented into Germany, the United Kingdom, France, Italy, Spain, Poland, Romania, Serbia, Bulgaria, the Czech Republic, Belgium, Slovakia, Ireland, Hungary, Portugal, Lithuania, Austria, Bosnia and Herzegovina, Latvia, the Netherlands, Greece, and the Rest of Europe. Germany held the largest share in 2025.

The colistin market in Germany is witnessing growth, owing to the increasing prevalence of MDR infections in hospitals, where colistin is essential for managing BSI and sepsis. According to the European Centre for Disease Prevention and Control (ECDC), the 2024 Surveillance of Antimicrobial Resistance in Europe data reveal that carbapenem-resistant Enterobacterales rates rose by 5% from 2023 to 2024, boosting colistin demand for LRTI and UTIs via hospital pharmacies. In 2025, ECDC estimated a 3% increase in MDR Pseudomonas cases. New product developments include the EMA approval of aztreonam-avibactam in 2024, which was launched in German facilities as a colistin-sparing therapy for cystic fibrosis and VAP. Other instances encompass Germany's National AMR Strategy 2023-2025, which noted a 2% uptick in colistin nebulized solutions for tracheobronchitis in 2024, according to the Robert Koch Institute. The Federal Ministry of Food and Agriculture reported a 3% rise in veterinary colistin oral formulations for animal health gastrointestinal infections from 2023 to 2024, available through retail pharmacies. Furthermore, the 2025 strategy highlighted expanded topical applications for skin infections via online pharmacies, addressing central nervous system infections with bowel decontamination.

Europe Colistin Market Company Profiles

Some of the key players operating in the market include Livzon Pharmaceutical Group Inc, TZF Polfa S.A., Tecoland Corporation, Fujian Lifecome Biochemistry Limited, Zhejiang Shenghua Biok Chemical Company Limited, Xellia Pharmaceuticals ApS, Shandong LuKang Pharmaceutical Co., Ltd, Apeloa Pharmaceutical Co., Ltd., Norma Hellas S.A, and Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Colistin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise